- Home
- CAN vs ZNTL Comparison
CAN vs ZNTL Comparison
Compare CAN & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- ZNTL
- Stock Information
- Founded
- CAN 2013
- ZNTL 2014
- Country
- CAN Singapore
- ZNTL United States
- Employees
- CAN N/A
- ZNTL N/A
- Industry
- CAN Semiconductors
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- ZNTL Health Care
- Exchange
- CAN Nasdaq
- ZNTL Nasdaq
- Market Cap
- CAN 330.5M
- ZNTL 105.8M
- IPO Year
- CAN 2019
- ZNTL 2020
- Fundamental
- Price
- CAN $0.88
- ZNTL $1.41
- Analyst Decision
- CAN Strong Buy
- ZNTL Buy
- Analyst Count
- CAN 6
- ZNTL 7
- Target Price
- CAN $2.67
- ZNTL $8.60
- AVG Volume (30 Days)
- CAN 49.0M
- ZNTL 1.4M
- Earning Date
- CAN 08-14-2025
- ZNTL 08-08-2025
- Dividend Yield
- CAN N/A
- ZNTL N/A
- EPS Growth
- CAN N/A
- ZNTL N/A
- EPS
- CAN N/A
- ZNTL N/A
- Revenue
- CAN $317,009,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- CAN $115.67
- ZNTL N/A
- Revenue Next Year
- CAN $63.75
- ZNTL N/A
- P/E Ratio
- CAN N/A
- ZNTL N/A
- Revenue Growth
- CAN 65.68
- ZNTL N/A
- 52 Week Low
- CAN $0.53
- ZNTL $1.01
- 52 Week High
- CAN $3.27
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- CAN 69.27
- ZNTL 55.69
- Support Level
- CAN $0.67
- ZNTL $1.29
- Resistance Level
- CAN $1.12
- ZNTL $1.43
- Average True Range (ATR)
- CAN 0.08
- ZNTL 0.09
- MACD
- CAN 0.04
- ZNTL 0.02
- Stochastic Oscillator
- CAN 79.52
- ZNTL 80.00
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.